September 25, 2020
ARLINGTON, Va. — In response to the Food and Drug Administration’s (FDA) final rule permitting prescription drug importation, Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement.
“As the industry that serves as the backbone of the U.S. pharmaceutical supply chain, we remain concerned that the administration’s drug importation policies will threaten patient safety and provide no meaningful cost reductions.
“HDA and its members share FDA’s commitment to ensuring patients across the nation have access to safe, effective and affordable medicines, but believe drug importation will lead to additional costs for the healthcare system, regulators and patients and undermine the supply chain’s collaborative efforts to implement the Drug Supply Chain Security Act (DSCSA).”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.